
|Videos|July 7, 2020
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer
Author(s)Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management
3
Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer
4
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
5








































